TMO: Strong Q2 growth, AI-driven demand, and reshoring trends support a robust multi-year outlook
Organic growth and EPS exceeded expectations, with strong momentum in pharma, biotech, and industrial markets. AI and reshoring trends are fueling multi-year growth, while strategic M&A and capacity expansions support long-term targets of 7% organic growth by 2028.Based on Thermo Fisher Scientific…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.